Novo Nordisk A/S Slogs Through the Year

Novo Nordisk A/S Slogs Through the Year

Novo Nordisk (NYSE: NVO) continues to slog through the year, dealing with losing exclusivity on hormone-replacement therapy Vagifem and pricing pressure. The year-over-year comparison for Vagifem will go away, but expect continued pricing pressure next year. Fortunately Novo Nordisk has an opportunity to launch semaglutide; that will likely end up being its top-selling drug, and should make up for the lower prices.

Metric

First 9 Months 2017

Continue reading

Source: Fool.com